Latest Articles
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer - OncLive
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer OncLive
Published: March 15, 2025, 4:52 p.m.
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive
Published: Dec. 3, 2024, 5:11 p.m.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer - OncLive
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer OncLive
Published: July 1, 2024, 7 a.m.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer - OncLive
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer OncLive
Published: April 8, 2024, 7 a.m.
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer - OncLive
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer OncLive
Published: April 2, 2024, 7 a.m.
Link copied to clipboard!